Medicare to Offer $50 Monthly GLP-1 Coverage for Weight Loss Starting July 2026
The Centers for Medicare & Medicaid Services (CMS) will launch a temporary program on July 1, 2026, allowing select Medicare beneficiaries to access GLP-1 weight loss medications for $50 per month, according to a federal announcement. This 18-month demonstration project, called the GLP-1 Bridge program, marks a significant shift in federal coverage for obesity treatment, though it does not permanently alter existing restrictions on weight loss drug reimbursement.
Who Qualifies for the Program?
To enroll, beneficiaries must be 18 or older, enrolled in Medicare Part D or a Medicare Advantage plan with drug coverage, and meet specific clinical criteria. These include a body mass index (BMI) of 35 or higher, or a BMI of 30–34.9 with at least one comorbidity. Individuals with a BMI of 27–29.9 must also have at least one additional health condition. Patients already on GLP-1s for diabetes or liver disease will remain under standard Part D coverage.
Which Medications Are Covered?
The program applies to specific GLP-1s prescribed for weight loss. These medications, which can cost up to $1,300 monthly, are typically excluded from standard Medicare coverage under current federal law. The Bridge program operates outside of Part D, meaning beneficiaries will pay the $50 copay in addition to any existing out-of-pocket costs under their drug plan.
How Does the Program Work Financially?
Beneficiaries enrolled in the Bridge program will not have costs counted toward the Part D out-of-pocket maximum of $2,100 or True Out-of-Pocket (TrOOP) limits. Federal assistance programs like “Extra Help” also cannot reduce the $50 copay. Despite this, the low price point has drawn praise from medical experts. “This is $50 a month. It’s quite remarkable for these medications,” said Dr. Nancy Nielsen, a senior associate dean at the University at Buffalo.
How to Access the Medications?
Eligible patients do not need to enroll in the program directly. Instead, their prescribing physician will submit a prior authorization request to a central processor. Once approved, beneficiaries pay $50 at the pharmacy. The prior authorization remains valid through December 31, 2027, unless the medication changes. Medicare provides an online checklist to help applicants determine eligibility.
What Happens When the Program Ends?
The Bridge program’s temporary nature raises concerns about long-term access. “The majority of patients experience significant weight regain if treatment with GLP-1 medications stops,” said Dr. Thomas Tsai, an associate professor at Harvard T.H. Chan School of Public Health. While the program represents a historic step, it does not resolve the broader debate over federal coverage of obesity treatments. “I hope it continues for more than 18 months,” Nielsen said, “but this is an amazing thing.”
Why This Matters for Medicare Beneficiaries
The program addresses a critical gap in care for older adults with obesity, a condition linked to heart disease, diabetes, and other chronic illnesses. However, its short duration and limited scope mean many beneficiaries may still face financial barriers. Advocates argue that the Bridge program could serve as a model for permanent coverage.